Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2018, Article ID 7934362, 15 pages
https://doi.org/10.1155/2018/7934362
Research Article

TRAIL-Dependent Resolution of Pulmonary Fibrosis

1Women’s Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2Immunology Group, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48103, USA
3Urologic Oncology Program and Uro-Oncology Research Laboratories, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
4Department of Molecular Cell Biology, Faculty of Medicine, Vrije Universiteit, Vrije Universiteit Medisch Centrum, 1081 BT Amsterdam, Netherlands

Correspondence should be addressed to David M. Habiel; gro.shsc@leibah.divad and Cory M. Hogaboam; gro.shsc@maobagoh.yroc

Received 7 August 2017; Accepted 2 November 2017; Published 24 January 2018

Academic Editor: Ruchi Bansal

Copyright © 2018 David M. Habiel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. M. du Bois, “Strategies for treating idiopathic pulmonary fibrosis,” Nature Reviews Drug Discovery, vol. 9, no. 2, pp. 129–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Gan, E. L. Herzog, and R. H. Gomer, “Pirfenidone treatment of idiopathic pulmonary fibrosis,” Therapeutics and Clinical Risk Management, vol. 7, pp. 39–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. P. W. Noble, C. Albera, W. Z. Bradford et al., “Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials,” The Lancet, vol. 377, no. 9779, pp. 1760–1769, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Drakopanagiotakis, A. Xifteri, V. Polychronopoulos, and D. Bouros, “Apoptosis in lung injury and fibrosis,” European Respiratory Journal, vol. 32, no. 6, pp. 1631–1638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. T. A. Wynn, “Integrating mechanisms of pulmonary fibrosis,” The Journal of Experimental Medicine, vol. 208, no. 7, pp. 1339–1350, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Hecker and V. J. Thannickal, “Nonresolving fibrotic disorders: idiopathic pulmonary fibrosis as a paradigm of impaired tissue regeneration,” The American Journal of the Medical Sciences, vol. 341, no. 6, pp. 431–434, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Kuwano, N. Hagimoto, and Y. Nakanishi, “The role of apoptosis in pulmonary fibrosis,” Histology and Histopathology, vol. 19, no. 3, pp. 867–881, 2004. View at Publisher · View at Google Scholar
  8. V. J. Thannickal, G. B. Toews, E. S. White, J. P. Lynch III, and F. J. Martinez, “Mechanisms of pulmonary fibrosis,” Annual Review of Medicine, vol. 55, no. 1, pp. 395–417, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. V. J. Thannickal and J. C. Horowitz, “Evolving concepts of apoptosis in idiopathic pulmonary fibrosis,” Proceedings of the American Thoracic Society, vol. 3, no. 4, pp. 350–356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Tanaka, M. Yoshimi, T. Maeyama, N. Hagimoto, K. Kuwano, and N. Hara, “Resistance to Fas-mediated apoptosis in human lung fibroblast,” European Respiratory Journal, vol. 20, no. 2, pp. 359–368, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Golan-Gerstl, S. B. Wallach-Dayan, P. Zisman, W. V. Cardoso, R. H. Goldstein, and R. Breuer, “Cellular FLICE-like inhibitory protein deviates myofibroblast Fas-induced apoptosis toward proliferation during lung fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 47, no. 3, pp. 271–279, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. R. S. Nho, M. Peterson, P. Hergert, and C. A. Henke, “FoxO3a (forkhead box O3a) deficiency protects idiopathic pulmonary fibrosis (IPF) fibroblasts from type I polymerized collagen matrix-induced apoptosis via caveolin-1 (cav-1) and Fas,” PLoS One, vol. 8, no. 4, article e61017, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Ricci, E. Cherubini, D. Scozzi et al., “Decreased expression of autophagic beclin 1 protein in idiopathic pulmonary fibrosis fibroblasts,” Journal of Cellular Physiology, vol. 228, no. 7, pp. 1516–1524, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Zhou, X. Huang, L. Hecker et al., “Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis,” The Journal of Clinical Investigation, vol. 123, no. 3, pp. 1096–1108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. E. E. McGrath, A. Lawrie, H. M. Marriott et al., “Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis,” Thorax, vol. 67, no. 9, pp. 796–803, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. B. R. Chaudhari, R. F. Murphy, and D. K. Agrawal, “Following the TRAIL to apoptosis,” Immunologic Research, vol. 35, no. 3, pp. 249–262, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. R. Loebinger, A. Eddaoudi, D. Davies, and S. M. Janes, “Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer,” Cancer Research, vol. 69, no. 10, pp. 4134–4142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Rojas, J. Xu, C. R. Woods et al., “Bone marrow–derived mesenchymal stem cells in repair of the injured lung,” American Journal of Respiratory Cell and Molecular Biology, vol. 33, no. 2, pp. 145–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Hashimoto, H. Jin, T. Liu, S. W. Chensue, and S. H. Phan, “Bone marrow–derived progenitor cells in pulmonary fibrosis,” The Journal of Clinical Investigation, vol. 113, no. 2, pp. 243–252, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Zhang, L. Zhang, H.-s. Jiang et al., “Mobilization of bone marrow cells by CSF3 protects mice from bleomycin-induced lung injury,” Respiration, vol. 82, no. 4, pp. 358–368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C. P. Jones and S. M. Rankin, “Bone marrow-derived stem cells and respiratory disease,” Chest, vol. 140, no. 1, pp. 205–211, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. V. N. Lama, “The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond,” Proceedings of the American Thoracic Society, vol. 3, no. 4, pp. 373–376, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Nita, K. Hostettler, L. Tamo et al., “Hepatocyte growth factor secreted by bone marrow stem cell reduce ER stress and improves repair in alveolar epithelial II cells,” Scientific Reports, vol. 7, p. 41901, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Wecht and M. Rojas, “Mesenchymal stem cells in the treatment of chronic lung disease,” Respirology, vol. 21, no. 8, pp. 1366–1375, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Liu, X. Zeng, J. Wang et al., “Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis,” Stem Cell Research & Therapy, vol. 7, no. 1, p. 63, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Boxio, C. Bossenmeyer-Pourié, N. Steinckwich, C. Dournon, and O. Nüsse, “Mouse bone marrow contains large numbers of functionally competent neutrophils,” Journal of Leukocyte Biology, vol. 75, no. 4, pp. 604–611, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. P. A. Chervenick, D. R. Boggs, J. C. Marsh, G. E. Cartwright, and M. M. Wintrobe, “Quantitative studies of blood and bone marrow neutrophils in normal mice,” The American Journal of Physiology, vol. 215, no. 2, pp. 353–360, 1968. View at Google Scholar
  28. Z. Zhou, D. L. French, G. Ma et al., “Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells,” Stem Cells, vol. 28, no. 3, pp. 620–632, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Arora, S. L. Poe, T. B. Oriss et al., “TLR4/MyD88-induced CD11b+Gr-1intF4/80+ non-migratory myeloid cells suppress Th2 effector function in the lung,” Mucosal Immunology, vol. 3, no. 6, pp. 578–593, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J.-I. Youn and D. I. Gabrilovich, “The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity,” European Journal of Immunology, vol. 40, no. 11, pp. 2969–2975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. M. R. Young, M. Newby, and H. T. Wepsic, “Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors,” Cancer Research, vol. 47, no. 1, pp. 100–105, 1987. View at Google Scholar
  32. I. G. Winkler, N. A. Sims, A. R. Pettit et al., “Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs,” Blood, vol. 116, no. 23, pp. 4815–4828, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Chow, D. Lucas, A. Hidalgo et al., “Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche,” The Journal of Experimental Medicine, vol. 208, no. 2, pp. 261–271, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. C. M. Hogaboam, N. W. Lukacs, S. W. Chensue, R. M. Strieter, and S. L. Kunkel, “Monocyte chemoattractant protein-1 synthesis by murine lung fibroblasts modulates CD4+ T cell activation,” The Journal of Immunology, vol. 160, no. 9, pp. 4606–4614, 1998. View at Google Scholar
  35. A. P. Moreira, K. A. Cavassani, U. B. Ismailoglu et al., “The protective role of TLR6 in a mouse model of asthma is mediated by IL-23 and IL-17A,” The Journal of Clinical Investigation, vol. 121, no. 11, pp. 4420–4432, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Jakubzick, E. S. Choi, S. L. Kunkel et al., “Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia,” Journal of Clinical Pathology, vol. 57, no. 5, pp. 477–486, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Jakubzick, E. S. Choi, K. J. Carpenter et al., “Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia,” The American Journal of Pathology, vol. 164, no. 6, pp. 1989–2001, 2004. View at Publisher · View at Google Scholar
  38. T. F. Greten, M. P. Manns, and F. Korangy, “Myeloid derived suppressor cells in human diseases,” International Immunopharmacology, vol. 11, no. 7, pp. 802–807, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Pastuła and J. Marcinkiewicz, “Myeloid-derived suppressor cells: a double-edged sword?” International Journal of Experimental Pathology, vol. 92, no. 2, pp. 73–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Choi, J.-W. Chang, and Y.-K. Jung, “Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling 6complex formation by binding to death effector domain caspase,” Cell Death and Differentiation, vol. 18, no. 3, pp. 405–414, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. B. B. Moore and C. M. Hogaboam, “Murine models of pulmonary fibrosis,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 294, no. 2, pp. L152–L160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Jiao, A. C. Dragomir, P. Kocabayoglu et al., “Central role of conventional dendritic cells in regulation of bone marrow release and survival of neutrophils,” The Journal of Immunology, vol. 192, no. 7, pp. 3374–3382, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Trujillo, E. C. O'Connor, S. L. Kunkel, and C. M. Hogaboam, “A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycin-induced pulmonary fibrosis,” The American Journal of Pathology, vol. 172, no. 5, pp. 1209–1221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. H.-S. Jiang, H.-P. Li, Y. Hu et al., “The effect of autologous bone marrow-derived cells mobilized by granulocyte colony stimulating factor on bleomycin-induced lung injury in mice,” Chinese Journal of Tuberculosis and Respiratory Diseases, vol. 32, no. 12, pp. 902–907, 2009. View at Google Scholar
  45. V. Bronte and P. Zanovello, “Regulation of immune responses by L-arginine metabolism,” Nature Reviews Immunology, vol. 5, no. 8, pp. 641–654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Ray, M. Arora, S. L. Poe, and A. Ray, “Lung myeloid-derived suppressor cells and regulation of inflammation,” Immunologic Research, vol. 50, no. 2-3, pp. 153–158, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Jakubzick, S. L. Kunkel, R. K. Puri, and C. M. Hogaboam, “Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis,” Immunologic Research, vol. 30, no. 3, pp. 339–350, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Desmoulière, M. Redard, I. Darby, and G. Gabbiani, “Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar,” The American Journal of Pathology, vol. 146, no. 1, pp. 56–66, 1995. View at Google Scholar
  49. Y. Koga, A. Matsuzaki, A. Suminoe, H. Hattori, and T. Hara, “Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL),” Cancer Research, vol. 64, no. 3, pp. 1037–1043, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. H. D. Singh, I. Otano, K. Rombouts et al., “TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis,” Scientific Reports, vol. 7, no. 1, p. 5514, 2017. View at Publisher · View at Google Scholar
  51. S. P. Cartland, H. H. Harith, S. W. Genner et al., “Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice,” Scientific Reports, vol. 7, no. 1, p. 1898, 2017. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Arabpour, R. H. Cool, K. N. Faber, W. J. Quax, and H. J. Haisma, “Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells,” Journal of Drug Targeting, vol. 25, no. 4, pp. 360–369, 2017. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Xu, D. Zhou, X. Meng et al., “Smad2 increases the apoptosis of activated human hepatic stellate cells induced by TRAIL,” International Immunopharmacology, vol. 32, pp. 76–86, 2016. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Oh, O. Park, M. Swierczewska et al., “Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells,” Hepatology, vol. 64, no. 1, pp. 209–223, 2016. View at Publisher · View at Google Scholar · View at Scopus
  55. K. M. Akram, N. J. Lomas, N. R. Forsyth, and M. A. Spiteri, “Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 2, pp. 552–564, 2014. View at Google Scholar
  56. L. A. Murray, H. Zhang, S. R. Oak et al., “Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 5, pp. 985–994, 2014. View at Publisher · View at Google Scholar · View at Scopus